PAVmed Inc. (NASDAQ:PAVM) Short Interest Down 25.8% in February

PAVmed Inc. (NASDAQ:PAVM) was the target of a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 262,500 shares, a decline of 25.8% from the January 31st total of 354,000 shares. Currently, 2.7% of the shares of the company are sold short. Based on an average trading volume of 211,600 shares, the days-to-cover ratio is currently 1.2 days.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reduced their price objective on PAVmed from $21.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th.

Institutional Investors Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. First Manhattan CO. LLC. grew its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. First Manhattan CO. LLC. owned about 6.32% of PAVmed worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.93% of the company’s stock.

PAVmed Stock Performance

Shares of NASDAQ:PAVM traded down $0.03 on Tuesday, hitting $0.66. The company’s stock had a trading volume of 94,556 shares, compared to its average volume of 102,852. PAVmed has a 12 month low of $0.57 and a 12 month high of $3.16. The company has a market capitalization of $7.31 million, a price-to-earnings ratio of -0.15 and a beta of 1.19. The stock’s 50-day moving average is $0.67 and its two-hundred day moving average is $0.93.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.